Premature ejaculation is the most common male sexual dysfunction, with a prevalence of up to 20% among all men. However, it is often ignored due to both poor treatment efficacy and compliance. In this meta-analysis, the authors from China present compelling data that a combination of selective serotonin reuptake inhibitors (SSRIs) and phosphodiesterase-5 (PDE-5) inhibitors is more efficacious than monotherapy for the treatment of premature ejaculation. Men with premature ejaculation could have an underlying erectile dysfunction that will extend the duration of erection with PDE5i, which is probably why dual therapy is more efficacious. The combined use of SSRIs and PDE-5 inhibitors provided additive favorable effects in men with PE compared with SSRIs or PDE-5 inhibitors monotherapy and was generally well tolerated. Urology: October 2015 Volume 86, Issue 4, Pages 758–765